Home LiteratureArticle Details
PMID: 21631264 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Molecular signatures of pancreatic cancer.

Archives of pathology & laboratory medicine ·Vol. 135 ·No. 6 ·2011-06-00 ·Pages 716-27

Hong SM, Park JY, Hruban RH, Goggins M

Abstract

The introduction of genome- and epigenome-wide screening techniques has dramatically improved our understanding of the molecular mechanisms underlying the development of pancreatic cancer. There are now 3 recognized histologic precursors of pancreatic cancer: pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and mucinous cystic neoplasm. Each of these precursor lesions is associated with specific molecular alterations. To understand the molecular characteristics of pancreatic ductal adenocarcinoma and its precursor lesions. PubMed (US National Library of Medicine). In this review, we briefly summarize recent research findings on the genetics and epigenetics of pancreatic cancer. In addition, we characterize these molecular alterations in the context of the histologic subtypes of pancreatic cancer.

MeSH Terms
Biomarkers, Tumor/genetics Carcinoma in Situ/classification,genetics,pathology Carcinoma, Pancreatic Ductal/classification,genetics,pathology Combined Modality Therapy Epigenesis, Genetic Gene Expression Regulation, Neoplastic Humans Pancreatic Neoplasms/classification,genetics,pathology Precancerous Conditions/classification,genetics,pathology PubMed
Chemicals
Biomarkers, Tumor
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Hong Seung-Mo
Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Park Jason Y
Hruban Ralph H
Goggins Michael
References (158)
158 references, click to expand
  1. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas.
    Mol Carcinog. 1998 Feb;21(2):81-6 PMID: 9496907
  2. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays.
    Am J Pathol. 2003 Apr;162(4):1151-62 PMID: 12651607
  3. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.
    Gastroenterology. 2002 Jul;123(1):365-72 PMID: 12105864
  4. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.
    Cancer Res. 1994 Jun 1;54(11):3025-33 PMID: 8187092
  5. The fundamental role of epigenetic events in cancer.
    Nat Rev Genet. 2002 Jun;3(6):415-28 PMID: 12042769
  6. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.
    Genes Dev. 1995 Mar 15;9(6):639-49 PMID: 7729683
  7. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas.
    Am J Pathol. 2000 Sep;157(3):755-61 PMID: 10980115
  8. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.
    J Clin Oncol. 2009 Apr 10;27(11):1806-13 PMID: 19273710
  9. Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas.
    Mod Pathol. 2003 Nov;16(11):1086-94 PMID: 14614047
  10. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers.
    Am J Pathol. 1999 Jun;154(6):1835-40 PMID: 10362809
  11. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene.
    Cancer Res. 1998 Jun 1;58(11):2339-42 PMID: 9622070
  12. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function.
    Cancer Res. 2007 Feb 15;67(4):1419-23 PMID: 17308078
  13. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis.
    World J Surg. 2009 Apr;33(4):698-709 PMID: 19030927
  14. K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: genetic evidence to support origin from the duct epithelium.
    Am J Surg Pathol. 1998 Oct;22(10):1247-54 PMID: 9777987
  15. Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control.
    Neoplasia. 2003 Sep-Oct;5(5):427-36 PMID: 14670180
  16. microRNAs as oncogenes and tumor suppressors.
    Dev Biol. 2007 Feb 1;302(1):1-12 PMID: 16989803
  17. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.
    Nat Genet. 1994 Sep;8(1):27-32 PMID: 7726912
  18. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma.
    Mod Pathol. 2009 May;22(5):651-9 PMID: 19270646
  19. Genome-wide allelotypes of familial pancreatic adenocarcinomas and familial and sporadic intraductal papillary mucinous neoplasms.
    Clin Cancer Res. 2007 Oct 15;13(20):6019-25 PMID: 17947463
  20. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling.
    Oncogene. 2004 Feb 26;23(8):1531-8 PMID: 14716296
  21. DNA methylation regulates MicroRNA expression.
    Cancer Biol Ther. 2007 Aug;6(8):1284-8 PMID: 17660710
  22. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets.
    Am J Pathol. 2003 Oct;163(4):1255-60 PMID: 14507635
  23. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions.
    Am J Surg Pathol. 2001 May;25(5):579-86 PMID: 11342768
  24. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds.
    Cancer Res. 2004 Apr 1;64(7):2634-8 PMID: 15059921
  25. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.
    Am J Pathol. 2000 Jan;156(1):37-43 PMID: 10623651
  26. Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas.
    Mod Pathol. 2008 Dec;21(12):1499-507 PMID: 18820670
  27. Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression.
    Am J Surg Pathol. 2000 Nov;24(11):1544-8 PMID: 11075857
  28. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.
    Science. 2009 Apr 10;324(5924):217 PMID: 19264984
  29. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas.
    Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 PMID: 9351717
  30. The genetics of hereditary colon cancer.
    Genes Dev. 2007 Oct 15;21(20):2525-38 PMID: 17938238
  31. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma.
    Cancer Res. 2001 Dec 1;61(23):8540-6 PMID: 11731440
  32. Hamartomatous polyposis syndromes.
    Nat Clin Pract Gastroenterol Hepatol. 2007 Sep;4(9):492-502 PMID: 17768394
  33. CpG-rich islands and the function of DNA methylation.
    Nature. 1986 May 15-21;321(6067):209-13 PMID: 2423876
  34. Precursors to invasive pancreatic cancer.
    Adv Anat Pathol. 2005 Mar;12(2):81-91 PMID: 15731576
  35. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma.
    Cancer Biol Ther. 2008 Jul;7(7):1146-56 PMID: 18535405
  36. PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
    Langenbecks Arch Surg. 2008 May;393(3):289-96 PMID: 18343945
  37. Molecular classification of neoplasms of the pancreas.
    Hum Pathol. 2009 May;40(5):612-23 PMID: 19362631
  38. Silencing of microRNAs in vivo with 'antagomirs'.
    Nature. 2005 Dec 1;438(7068):685-9 PMID: 16258535
  39. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma.
    Cancer Res. 1997 Jun 1;57(11):2140-3 PMID: 9187111
  40. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.
    Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3636-41 PMID: 8622988
  41. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer.
    Nat Rev Cancer. 2003 Nov;3(11):807-21 PMID: 14557817
  42. Isolation and characterization of the cDNA encoding human DNA methyltransferase.
    Nucleic Acids Res. 1992 May 11;20(9):2287-91 PMID: 1594447
  43. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation.
    Am J Pathol. 2002 Jan;160(1):45-50 PMID: 11786397
  44. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays.
    Cancer Res. 2003 Jul 1;63(13):3735-42 PMID: 12839967
  45. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.
    J Clin Oncol. 2007 Jan 20;25(3):319-25 PMID: 17235047
  46. Identification and characterization of the familial adenomatous polyposis coli gene.
    Cell. 1991 Aug 9;66(3):589-600 PMID: 1651174
  47. Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers.
    Gastroenterology. 2006 Feb;130(2):548-65 PMID: 16472607
  48. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels.
    Cancer Res. 2010 Jul 1;70(13):5226-37 PMID: 20551052
  49. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer.
    Clin Cancer Res. 2008 Jan 15;14(2):412-8 PMID: 18223216
  50. Cancer genes and the pathways they control.
    Nat Med. 2004 Aug;10(8):789-99 PMID: 15286780
  51. Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models.
    Clin Cancer Res. 2007 Jan 1;13(1):4-10 PMID: 17200332
  52. Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas and periampullary region.
    Cancer. 1998 Apr 1;82(7):1279-87 PMID: 9529019
  53. Hypermethylation of multiple genes in pancreatic adenocarcinoma.
    Cancer Res. 2000 Apr 1;60(7):1835-9 PMID: 10766168
  54. Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases.
    J Mol Biol. 1988 Oct 20;203(4):971-83 PMID: 3210246
  55. A microRNA expression signature of human solid tumors defines cancer gene targets.
    Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 PMID: 16461460
  56. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis.
    Mol Cell. 2007 Jun 8;26(5):745-52 PMID: 17540599
  57. Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma.
    Leuk Lymphoma. 2007 Feb;48(2):410-2 PMID: 17325905
  58. Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin.
    J Pathol. 1998 May;185(1):53-60 PMID: 9713360
  59. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family.
    PLoS Med. 2004 Dec;1(3):e65 PMID: 15630470
  60. Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors.
    Clin Cancer Res. 2004 Mar 1;10(5):1597-604 PMID: 15014009
  61. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia.
    Cancer Biol Ther. 2009 Feb;8(4):340-6 PMID: 19106647
  62. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
    Virchows Arch. 2001 Dec;439(6):798-802 PMID: 11787853
  63. Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma.
    Cancer. 2006 Jul 15;107(2):251-7 PMID: 16752411
  64. Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases.
    Am J Surg Pathol. 1999 Jan;23(1):1-16 PMID: 9888699
  65. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
    Nature. 2005 Apr 14;434(7035):913-7 PMID: 15829966
  66. Origin of giant cells in osteoclast-like giant cell tumors of the pancreas.
    Hum Pathol. 2000 Oct;31(10):1223-9 PMID: 11070115
  67. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.
    Cancer Biol Ther. 2009 Nov;8(21):2013-24 PMID: 20037478
  68. Hypomethylation distinguishes genes of some human cancers from their normal counterparts.
    Nature. 1983 Jan 6;301(5895):89-92 PMID: 6185846
  69. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions.
    Oncogene. 2003 Aug 7;22(32):5021-30 PMID: 12902985
  70. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.
    Am J Pathol. 2002 May;160(5):1573-81 PMID: 12000709
  71. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma.
    Pancreatology. 2010;10(1):66-73 PMID: 20332664
  72. Colloid (mucinous noncystic) carcinoma of the pancreas.
    Am J Surg Pathol. 2001 Jan;25(1):26-42 PMID: 11145249
  73. Very high risk of cancer in familial Peutz-Jeghers syndrome.
    Gastroenterology. 2000 Dec;119(6):1447-53 PMID: 11113065
  74. The epigenomics of cancer.
    Cell. 2007 Feb 23;128(4):683-92 PMID: 17320506
  75. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer.
    PLoS Genet. 2008 May 23;4(5):e1000081 PMID: 18535672
  76. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis.
    Gut. 1993 Oct;34(10):1394-6 PMID: 8244108
  77. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues.
    Clin Cancer Res. 2003 Apr;9(4):1446-52 PMID: 12684418
  78. Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats.
    Cancer Res. 1995 May 1;55(9):1894-901 PMID: 7794383
  79. MicroRNAs in cell proliferation, cell death, and tumorigenesis.
    Br J Cancer. 2006 Mar 27;94(6):776-80 PMID: 16495913
  80. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms.
    Br J Cancer. 2003 Jul 21;89(2):338-43 PMID: 12865927
  81. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.
    Science. 1996 Jan 19;271(5247):350-3 PMID: 8553070
  82. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas.
    Am J Surg Pathol. 2004 Jul;28(7):839-48 PMID: 15223952
  83. Pathology of incipient pancreatic cancer.
    Ann Oncol. 1999;10 Suppl 4:9-11 PMID: 10436775
  84. c-Myc-regulated microRNAs modulate E2F1 expression.
    Nature. 2005 Jun 9;435(7043):839-43 PMID: 15944709
  85. The genetics of FANCC and FANCG in familial pancreatic cancer.
    Cancer Biol Ther. 2004 Feb;3(2):167-9 PMID: 14726700
  86. Number of CpG islands and genes in human and mouse.
    Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11995-9 PMID: 7505451
  87. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.
    Clin Cancer Res. 2008 Nov 1;14(21):7151-7 PMID: 18981015
  88. Update on pancreatic intraepithelial neoplasia.
    Int J Clin Exp Pathol. 2008 Jan 01;1(4):306-16 PMID: 18787611
  89. Hereditary pancreatitis: clinical features and inheritance characteristics of the R122C mutation in the cationic trypsinogen gene (PRSS1) in six Spanish families.
    JOP. 2009 May 18;10(3):249-55 PMID: 19454815
  90. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity.
    Am J Pathol. 2000 May;156(5):1641-51 PMID: 10793075
  91. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma.
    Oncogene. 2007 Jun 28;26(30):4442-52 PMID: 17237814
  92. Age- and disease-related methylation of multiple genes in nonneoplastic duodenum and in duodenal juice.
    Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):573-83 PMID: 15701843
  93. Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets?
    Histopathology. 2010 Mar;56(4):440-8 PMID: 20459551
  94. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene.
    Nat Genet. 1996 Oct;14(2):141-5 PMID: 8841182
  95. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.
    Virchows Arch. 1994;425(4):357-67 PMID: 7820300
  96. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling.
    Clin Cancer Res. 2005 Jul 1;11(13):4681-8 PMID: 16000561
  97. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    N Engl J Med. 2003 Jul 17;349(3):247-57 PMID: 12867608
  98. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+.
    Am J Pathol. 1998 Jun;152(6):1501-7 PMID: 9626054
  99. Cancer statistics, 2010.
    CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300 PMID: 20610543
  100. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation.
    Cancer Res. 2005 Nov 1;65(21):9628-32 PMID: 16266980
  101. Epigenetics by DNA methylation for development of normal and cloned animals.
    Differentiation. 2002 Jan;69(4-5):162-6 PMID: 11841471
  102. Pancreatic adenocarcinomas frequently show p53 gene mutations.
    Am J Pathol. 1993 May;142(5):1534-43 PMID: 8494051
  103. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
    Am J Pathol. 1993 Aug;143(2):545-54 PMID: 8342602
  104. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage.
    Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3290-5 PMID: 9096386
  105. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.
    Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 PMID: 12434020
  106. SPINK1/PSTI mutations are associated with tropical pancreatitis and type II diabetes mellitus in Bangladesh.
    Gastroenterology. 2002 Oct;123(4):1026-30 PMID: 12360464
  107. BRCA2 germline mutations in familial pancreatic carcinoma.
    J Natl Cancer Inst. 2003 Feb 5;95(3):214-21 PMID: 12569143
  108. Expression profiling identifies microRNA signature in pancreatic cancer.
    Int J Cancer. 2007 Mar 1;120(5):1046-54 PMID: 17149698
  109. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.
    Cancer Biol Ther. 2005 Sep;4(9):934-6 PMID: 16251802
  110. Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines.
    Oncogene. 2004 Mar 25;23(13):2401-7 PMID: 14743205
  111. Frequent genomic copy number gain and overexpression of GATA-6 in pancreatic carcinoma.
    Cancer Biol Ther. 2008 Oct;7(10):1593-601 PMID: 18769116
  112. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families.
    Melanoma Res. 1995 Jun;5(3):169-77 PMID: 7640518
  113. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?
    Am J Hum Genet. 1998 May;62(5):1044-51 PMID: 9545395
  114. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma.
    Oncogene. 2005 Jan 27;24(5):850-8 PMID: 15592528
  115. Familial pancreatic cancer.
    Arch Pathol Lab Med. 2009 Mar;133(3):365-74 PMID: 19260742
  116. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
    Cancer Res. 1998 Dec 1;58(23):5329-32 PMID: 9850059
  117. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.
    JAMA. 2007 May 2;297(17):1901-8 PMID: 17473300
  118. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.
    Cancer Res. 1997 Oct 1;57(19):4177-82 PMID: 9331070
  119. Prognostic value of microsatellite instability in resectable pancreatic cancer.
    Clin Cancer Res. 2002 Aug;8(8):2536-40 PMID: 12171881
  120. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.
    J Med Genet. 2005 Sep;42(9):711-9 PMID: 16141007
  121. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma.
    Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3254-7 PMID: 11248065
  122. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group.
    J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 PMID: 9091646
  123. Pancreaticobiliary cancers with deficient methylenetetrahydrofolate reductase genotypes.
    Clin Gastroenterol Hepatol. 2005 Aug;3(8):752-60 PMID: 16234003
  124. Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs.
    Cancer Biol Ther. 2002 May-Jun;1(3):293-6 PMID: 12432281
  125. Widespread microRNA repression by Myc contributes to tumorigenesis.
    Nat Genet. 2008 Jan;40(1):43-50 PMID: 18066065
  126. Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: Coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas.
    Am J Surg Pathol. 2003 May;27(5):571-8 PMID: 12717243
  127. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.
    Cancer Cell. 2006 Jun;9(6):435-43 PMID: 16766263
  128. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas.
    Am J Pathol. 2001 Dec;159(6):2017-22 PMID: 11733352
  129. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
    Clin Cancer Res. 2005 Oct 15;11(20):7508-15 PMID: 16243825
  130. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.
    Genes Dev. 1995 Mar 15;9(6):650-62 PMID: 7729684
  131. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival.
    J Gastrointest Surg. 2008 Dec;12(12):2171-6 PMID: 18642050
  132. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia.
    Am J Pathol. 2002 Nov;161(5):1541-7 PMID: 12414502
  133. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma.
    Clin Cancer Res. 2001 Dec;7(12):4115-21 PMID: 11751510
  134. Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors.
    Cancer Biol Ther. 2010 Feb;9(4):321-9 PMID: 20234167
  135. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
    Cancer Res. 1996 Dec 1;56(23):5360-4 PMID: 8968085
  136. Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters.
    PLoS Genet. 2007 Oct;3(10):2023-36 PMID: 17967063
  137. Negative hMSH2 protein expression in pancreatic carcinoma may predict a better prognosis of patients.
    Oncol Rep. 2003 Jul-Aug;10(4):997-1000 PMID: 12792759
  138. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease.
    Gastroenterology. 1996 Jan;110(1):227-31 PMID: 8536861
  139. Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas.
    Cancer Lett. 2003 Sep 25;199(2):193-200 PMID: 12969792
  140. DPC4 gene in various tumor types.
    Cancer Res. 1996 Jun 1;56(11):2527-30 PMID: 8653691
  141. CpG island methylation profile of pancreatic intraepithelial neoplasia.
    Mod Pathol. 2008 Mar;21(3):238-44 PMID: 18157091
  142. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
    Science. 2008 Sep 26;321(5897):1801-6 PMID: 18772397
  143. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability.
    Cancer Res. 2001 Apr 1;61(7):3139-44 PMID: 11306499
  144. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.
    Br J Cancer. 1997;76(10):1293-9 PMID: 9374374
  145. Pancreatic cancer.
    Annu Rev Pathol. 2008;3:157-88 PMID: 18039136
  146. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer.
    Cancer Res. 2004 Aug 1;64(15):5338-46 PMID: 15289340
  147. The 5-methylcytosine content of DNA from human tumors.
    Nucleic Acids Res. 1983 Oct 11;11(19):6883-94 PMID: 6314264
  148. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.
    Cancer Res. 2000 Apr 1;60(7):2002-6 PMID: 10766191
  149. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy.
    Ann Surg. 1999 Oct;230(4):501-9; discussion 509-11 PMID: 10522720
  150. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
    Cancer Res. 1997 Aug 1;57(15):3126-30 PMID: 9242437
  151. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome.
    Pancreas. 1991 Mar;6(2):127-31 PMID: 1886881
  152. Progression model for pancreatic cancer.
    Clin Cancer Res. 2000 Aug;6(8):2969-72 PMID: 10955772
  153. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases.
    Nat Genet. 1998 Jul;19(3):219-20 PMID: 9662389
  154. Ras redux: rethinking how and where Ras acts.
    Curr Opin Genet Dev. 2003 Feb;13(1):6-13 PMID: 12573429
  155. Undifferentiated carcinoma with osteoclastic giant cells (UCOCGC) of the pancreas associated with the familial atypical multiple mole melanoma syndrome (FAMMM).
    Am J Surg Pathol. 2008 Dec;32(12):1905-9 PMID: 18813118
  156. Identification of FAP locus genes from chromosome 5q21.
    Science. 1991 Aug 9;253(5020):661-5 PMID: 1651562
  157. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma.
    Cancer Res. 2003 Jul 15;63(14):4158-66 PMID: 12874021
  158. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.
    Clin Cancer Res. 2009 Jul 15;15(14):4674-9 PMID: 19584151
Article Info
Journal
Archives of pathology & laboratory medicine
Abbr.
Arch Pathol Lab Med
ISSN
1543-2165
DOI
10.5858/2010-0566-RA.1
Published
2011-06-00
Pages
716-27
Language
English
Region
United States
NLM ID
7607091
PMCID
PMC3107523
Subset
IM
Grants
NCI NIH HHS · R01 CA120432 · United States
NCI NIH HHS · R01-CA120432 · United States
NCI NIH HHS · P50 CA102701 · United States
NCI NIH HHS · R01 CA120432-05 · United States
NCI NIH HHS · P50-CA62924 · United States
NCI NIH HHS · R01 CA097075 · United States
NCI NIH HHS · R01-CA97075 · United States
NCI NIH HHS · P50 CA062924 · United States
NCI NIH HHS · P50 CA062924-18 · United States
NCI NIH HHS · R01 CA097075-09 · United States
External Links
PubMed source DOI: 10.5858/2010-0566-RA.1 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2